| scholarly article | Q13442814 |
| P356 | DOI | 10.2337/DIAB.46.9.1473 |
| P698 | PubMed publication ID | 9287049 |
| P50 | author | Thomas A Ciulla | Q57159183 |
| P2093 | author name string | H Ishii | |
| L E Smith | |||
| L P Aiello | |||
| S E Bursell | |||
| F Mori | |||
| G L King | |||
| C Takagi | |||
| E Duh | |||
| K Ways | |||
| A Clermont | |||
| M Jirousek | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1473-1480 | |
| P577 | publication date | 1997-09-01 | |
| P1433 | published in | Diabetes | Q895262 |
| P1476 | title | Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor | |
| P478 | volume | 46 |
| Q35646181 | A Quantitative and Standardized Method for the Evaluation of Choroidal Neovascularization Using MICRON III Fluorescein Angiograms in Rats |
| Q33384375 | A phase I trial of enzastaurin in patients with recurrent gliomas |
| Q47890044 | A phase II trial of enzastaurin (LY317615) in combination with bevacizumab in adults with recurrent malignant gliomas |
| Q35027679 | A potential role for angiopoietin 2 in the regulation of the blood-retinal barrier in diabetic retinopathy |
| Q33355710 | A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema |
| Q84558890 | A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein |
| Q24646760 | A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal [...] |
| Q44070309 | Advanced glycation end products increase, through a protein kinase C-dependent pathway, vascular endothelial growth factor expression in retinal endothelial cells. Inhibitory effect of gliclazide |
| Q43095043 | Alternative therapies in exudative age related macular degeneration. |
| Q43946490 | Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders |
| Q37369097 | Angiotensin blockade to reduce microvascular damage in diabetes mellitus |
| Q74682412 | Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human breast cancer and ovarian cancer xenografts |
| Q34295974 | Antiangiogenic therapy for ischemic retinopathies |
| Q80350462 | Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients |
| Q33511170 | Aqueous vascular endothelial growth factor as a predictor of macular thickening following cataract surgery in patients with diabetes mellitus |
| Q37607650 | Beneficial effects of the nutritional supplements on the development of diabetic retinopathy |
| Q42123271 | Blockade of vascular endothelial growth factor receptor 1 prevents inflammation and vascular leakage in diabetic retinopathy. |
| Q48580864 | Bowman Lecture 1998. Diabetic retinopathy: some cellular, molecular and therapeutic considerations |
| Q36062252 | Cellular mechanisms and treatment of diabetes vascular complications converge on reactive oxygen species |
| Q37089750 | Cellular signaling and potential new treatment targets in diabetic retinopathy |
| Q31123332 | Changing times for the management of diabetic retinopathy |
| Q83008636 | Characteristics of diabetic retinopathy in SDT rats |
| Q28504628 | Characterization of protein kinase C beta isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization |
| Q38260400 | Cinnamon extract inhibits angiogenesis in zebrafish and human endothelial cells by suppressing VEGFR1, VEGFR2, and PKC-mediated MAP kinase |
| Q34241921 | Combination therapy for diabetic macular edema. |
| Q37463972 | Comparison between intravitreal bevacizumab and triamcinolone for macular edema secondary to branch retinal vein occlusion |
| Q35086234 | Complex regulation of PKCβ2 and PDK-1/AKT by ROCK2 in diabetic heart |
| Q53766666 | Consumption of polyphenol-rich Morus alba leaves extract attenuates early diabetic retinopathy: the underlying mechanism. |
| Q37084522 | Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy |
| Q31049802 | Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial |
| Q36796899 | Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema |
| Q43198819 | Counter regulatory effects of PKCbetaII and PKCdelta on coronary endothelial permeability |
| Q37221516 | Current and future approaches in the prevention and treatment of diabetic retinopathy. |
| Q37801912 | Current approaches to the management of diabetic retinopathy and diabetic macular oedema |
| Q37819879 | Current update on retinopathy of prematurity: screening and treatment |
| Q35768511 | Decreased K5 receptor expression in the retina, a potential pathogenic mechanism for diabetic retinopathy |
| Q37703235 | Delivery of celecoxib for treating diseases of the eye: influence of pigment and diabetes |
| Q42699559 | Diabetic Retinopathy and Laser Therapy in Rats: A Protein-Protein Interaction Network Analysis |
| Q37985854 | Diabetic macular edema: current and emerging therapies |
| Q34185374 | Diabetic macular edema: therapeutic options |
| Q30819244 | Diabetic macular oedema: a comparison of vitreous fluorometry, angiography, and retinopathy |
| Q36018006 | Diabetic macular oedema: pathophysiology, management challenges and treatment resistance |
| Q41012046 | Diabetic retinopathy and inflammation: novel therapeutic targets. |
| Q35545811 | Diabetic retinopathy, superoxide damage and antioxidants. |
| Q39451009 | Diabetic retinopathy: Breaking the barrier |
| Q39208422 | Diabetic retinopathy: new therapeutic perspectives based on pathogenic mechanisms. |
| Q34733351 | Diabetic vascular dysfunction: links to glucose-induced reductive stress and VEGF. |
| Q37733102 | Dietary hyperglycemia, glycemic index and metabolic retinal diseases |
| Q30631779 | Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor |
| Q36431788 | Early diabetes-induced biochemical changes in the retina: comparison of rat and mouse models |
| Q31035344 | Effect of staurosporine on cycle of human gastric cancer cells. |
| Q89002608 | Effectiveness of the Dexamethasone Intravitreal Implant for Treatment of Patients with Diabetic Macular Oedema |
| Q54396384 | Effects of Trigonella foenum-graecum (L.) on retinal oxidative stress, and proinflammatory and angiogenic molecular biomarkers in streptozotocin-induced diabetic rats. |
| Q35057237 | Effects of arteriolar constriction on retinal gene expression and Müller cell responses in a rat model of branch retinal vein occlusion |
| Q46970219 | Effects of chronic renal failure on the pharmacokinetics of ruboxistaurin and its active metabolite 338522. |
| Q33871118 | Effects of intravitreal triamcinolone acetonide on retinal gene expression in a rat model of central retinal vein occlusion |
| Q90138907 | Efficacy of intravitreal dexamethasone implant in persistent diabetic macular edema after primary treatment with intravitreal ranibizumab |
| Q86867595 | Efficacy of single-dose dexamethasone implantation in patients with persistent diabetic macular edema |
| Q58907881 | Emerging pharmacotherapies for diabetic macular edema |
| Q38404246 | EphrinA1 inhibits vascular endothelial growth factor-induced intracellular signaling and suppresses retinal neovascularization and blood-retinal barrier breakdown |
| Q35171497 | Evaluation of the Response to Ranibizumab Therapy following Bevacizumab Treatment Failure in Eyes with Diabetic Macular Edema |
| Q35745334 | Expression of thrombospondin-1 in ischemia-induced retinal neovascularization |
| Q35765120 | Expression of vascular endothelial growth factor in the human retina and in nonproliferative diabetic retinopathy. |
| Q28285595 | Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation |
| Q34022792 | Free insulin-like growth factor binding protein-3 (IGFBP-3) reduces retinal vascular permeability in association with a reduction of acid sphingomyelinase (ASMase). |
| Q26824541 | Functions of Müller cell-derived vascular endothelial growth factor in diabetic retinopathy |
| Q38585087 | Genetic difference in susceptibility to the blood-retina barrier breakdown in diabetes and oxygen-induced retinopathy |
| Q28362039 | Glucose, VEGF-A, and diabetic complications |
| Q35648554 | Growth factors and protein kinase C inhibitors as novel therapies for the medical management diabetic retinopathy |
| Q34804249 | Haemodynamics in microvascular complications in type 1 diabetes |
| Q34415658 | Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications |
| Q28344038 | In vivo mechanisms of vascular endothelial growth factor-mediated increased hydraulic conductivity of Rana capillaries |
| Q52537902 | Increased H2O2, vascular endothelial growth factor and receptors in the retina of the BBZ/Wor diabetic rat. |
| Q40299296 | Inflammatory and angiogenic protein detection in the human vitreous: cytometric bead assay |
| Q35818087 | Inflammatory cytokines in aqueous humor of patients with choroidal neovascularization. |
| Q64112936 | Inhibition of Aberrant IGF-I Signaling in Diabetic Male Rat Retina Prevents and Reverses Changes of Diabetic Retinopathy |
| Q80178769 | Inhibition of PKC beta by ruboxistaurin does not enhance the acute blood pressure response to nitroglycerin |
| Q42767408 | Inhibition of advanced glycation and absence of galectin-3 prevent blood-retinal barrier dysfunction during short-term diabetes. |
| Q33703836 | Inhibition of protein kinase C delta attenuates blood-retinal barrier breakdown in diabetic retinopathy |
| Q35928442 | Inhibition of the adrenomedullin/nitric oxide signaling pathway in early diabetic retinopathy |
| Q78763438 | Inhibitory effects of bucillamine on increased blood-retinal barrier permeability in streptozotocin-induced diabetic rats |
| Q63241384 | Interaction of Endothelin-1 with Vasoactive Factors in Mediating Glucose-Induced Increased Permeability in Endothelial Cells |
| Q35993746 | Interleukin-1β-induced barrier dysfunction is signaled through PKC-θ in human brain microvascular endothelium |
| Q33771458 | Intraocular soluble intracellular adhesion molecule-1 correlates with subretinal fluid height of diabetic macular edema |
| Q51935620 | Intravitreal triamcinolone acetonide for macular oedema owing to retinal vein occlusion. |
| Q36082148 | Introduction of hyperglycemia and dyslipidemia in the pathogenesis of diabetic vascular complications |
| Q36977415 | Introduction, mechanism of action and rationale for anti-vascular endothelial growth factor drugs in age-related macular degeneration |
| Q62698433 | Is blockade of vascular endothelial growth factor beneficial for all types of diabetic retinopathy? |
| Q43299871 | Is neuronal dysfunction an early sign of diabetic retinopathy? Microperimetry and spectral domain optical coherence tomography (SD-OCT) study in individuals with diabetes, but no diabetic retinopathy |
| Q62066203 | Long-term global retinal microvascular changes in a transgenic vascular endothelial growth factor mouse model |
| Q45888226 | Loss of placental growth factor protects mice against vascular permeability in pathological conditions |
| Q41015495 | Many Faces of Renin-angiotensin System - Focus on Eye. |
| Q35175679 | Medical treatment of diabetic retinopathy |
| Q37139800 | Mice deficient in PKCbeta and apolipoprotein E display decreased atherosclerosis |
| Q34741796 | Modulation of VEGF-induced retinal vascular permeability by peroxisome proliferator-activated receptor-β/δ. |
| Q27014620 | Molecular mechanisms of diabetic retinopathy, general preventive strategies, and novel therapeutic targets |
| Q33558421 | Molecular mechanisms of diabetic vascular complications |
| Q37535022 | Molecular mechanisms of endothelial hyperpermeability: implications in inflammation |
| Q97882525 | Morin attenuates STZ-induced diabetic retinopathy in experimental animals |
| Q36511716 | Multiplex bead analysis of vitreous and serum concentrations of inflammatory and proangiogenic factors in diabetic patients |
| Q37076073 | Myosin light chain kinase signaling in endothelial barrier dysfunction |
| Q36706288 | Müller cells as players in retinal degeneration and edema |
| Q37267083 | Nanoparticle-mediated expression of an angiogenic inhibitor ameliorates ischemia-induced retinal neovascularization and diabetes-induced retinal vascular leakage |
| Q35071239 | Neurovascular interaction and the pathophysiology of diabetic retinopathy |
| Q34313113 | Novel atypical PKC inhibitors prevent vascular endothelial growth factor-induced blood-retinal barrier dysfunction |
| Q34688209 | Novel drugs and their targets in the potential treatment of diabetic retinopathy |
| Q27002622 | Novel pharmacotherapies in diabetic retinopathy |
| Q37217856 | Novel potential mechanisms for diabetic macular edema: leveraging new investigational approaches |
| Q41116544 | Occludin downregulation in high glucose is regulated by SSTR2 via the VEGF/NRP1/Akt signaling pathway in RF/6A cells. |
| Q37344103 | Occludin phosphorylation and ubiquitination regulate tight junction trafficking and vascular endothelial growth factor-induced permeability |
| Q35049903 | Ocular complications of diabetes mellitus |
| Q34565454 | Ocular manifestations of von Hippel-Lindau disease: clinical and genetic investigations. |
| Q34975866 | Ocular perfusion abnormalities in diabetes. |
| Q44635831 | Opposing effect of angiopoietin‐1 on VEGF‐mediated disruption of endothelial cell–cell interactions requires activation of PKCβ |
| Q35819297 | Oxidative stress and diabetic retinopathy |
| Q37226580 | Oxidative stress and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives |
| Q38480783 | Oxidative stress and epigenetic modifications in the pathogenesis of diabetic retinopathy. |
| Q34498406 | Oxidative stress increases pulmonary vascular permeability in diabetic rats through activation of transient receptor potential melastatin 2 channels |
| Q33939170 | PEDF regulates vascular permeability by a γ-secretase-mediated pathway |
| Q34327850 | PKCbeta regulates ischemia/reperfusion injury in the lung |
| Q26865897 | Pathophysiology of diabetic retinopathy |
| Q44496983 | Perspectives on diabetic retinopathy |
| Q35827367 | Pharmacokinetics of ruboxistaurin are significantly altered by rifampicin-mediated CYP3A4 induction |
| Q33492340 | Pharmacologic therapies for diabetic retinopathy and diabetic macular edema |
| Q45183901 | Pharmacological treatment of diabetic retinopathy |
| Q33294882 | Pharmacotherapies for diabetic retinopathy: present and future |
| Q36294444 | Phosphorylation of pleckstrin increases proinflammatory cytokine secretion by mononuclear phagocytes in diabetes mellitus |
| Q43223636 | Pigment epithelium-derived factor inhibits vascular endothelial growth factor-and interleukin-1beta-induced vascular permeability and angiogenesis in retinal endothelial cells |
| Q35797036 | Plasma kallikrein mediates retinal vascular dysfunction and induces retinal thickening in diabetic rats |
| Q44686998 | Plasminogen kringle 5 reduces vascular leakage in the retina in rat models of oxygen-induced retinopathy and diabetes |
| Q35111433 | Population pharmacokinetics of pegaptanib sodium (Macugen(®)) in patients with diabetic macular edema |
| Q34626222 | Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors |
| Q35787073 | Pro-inflammatory cytokines induce expression of matrix-metabolizing enzymes in human cervical smooth muscle cells |
| Q35615435 | Protein kinase C inhibition and diabetic retinopathy: a shot in the dark at translational research |
| Q36187549 | Protein kinase C β inhibition by enzastaurin leads to mitotic missegregation and preferential cytotoxicity toward colorectal cancer cells with chromosomal instability (CIN) |
| Q35976653 | Protein kinase cβ phosphorylates occludin regulating tight junction trafficking in vascular endothelial growth factor-induced permeability in vivo |
| Q34440571 | Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy |
| Q34410824 | Ranibizumab, verteporfin photodynamic therapy or observation for the treatment of myopic choroidal neovascularization: cost effectiveness in the UK. |
| Q28396273 | Reactive oxygen species in inflammation and tissue injury |
| Q49118822 | Recombinant human angiopoietin-1 ameliorates the expressions of ZO-1, occludin, VE-cadherin, and PKCα signaling after focal cerebral ischemia/reperfusion in rats |
| Q33969514 | Regulators of vascular permeability: potential sites for intervention in the treatment of macular edema |
| Q36035854 | Relationship between perifoveal capillaries and pathomorphology in macular oedema associated with branch retinal vein occlusion |
| Q58762933 | Remodeling of Retinal Architecture in Diabetic Retinopathy: Disruption of Ocular Physiology and Visual Functions by Inflammatory Gene Products and Pyroptosis |
| Q99561828 | Retinal Physiology and Circulation: Effect of Diabetes |
| Q40730311 | Retinal expression, regulation, and functional bioactivity of prostacyclin-stimulating factor |
| Q44108814 | Retinal metabolic abnormalities in diabetic mouse: comparison with diabetic rat. |
| Q37122850 | Retinal not systemic oxidative and inflammatory stress correlated with VEGF expression in rodent models of insulin resistance and diabetes |
| Q35210888 | Retracted: Nuclear Factor Kappa-B Signaling Is Integral to Ocular Neovascularization in Ischemia-Independent Microenvironment |
| Q34475449 | Review of therapeutic advances in diabetic retinopathy |
| Q35181953 | Role of VEGF in kidney development, microvascular maintenance and pathophysiology of renal disease |
| Q26775853 | Role of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implant |
| Q34103169 | Role of vasoactive factors in the pathogenesis of early changes in diabetic retinopathy |
| Q33730079 | Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study |
| Q47879810 | Secretogranin III: a diabetic retinopathy-selective angiogenic factor. |
| Q34931190 | Selective PKC beta inhibition with ruboxistaurin and endothelial function in type-2 diabetes mellitus |
| Q44528945 | Serum-derived factors weaken the barrier properties of cultured porcine brain capillary endothelial cells in vitro |
| Q26774524 | Steroids in Central Retinal Vein Occlusion: Is There a Role in Current Treatment Practice? |
| Q38145185 | Structural changes in individual retinal layers in diabetic macular edema |
| Q33201162 | Surgery for macular edema |
| Q36287281 | Sustained pharmacological inhibition of deltaPKC protects against hypertensive encephalopathy through prevention of blood-brain barrier breakdown in rats |
| Q36894263 | Sustained-release ophthalmic drug delivery systems for treatment of macular disorders: present and future applications |
| Q34237700 | TNF-α signals through PKCζ/NF-κB to alter the tight junction complex and increase retinal endothelial cell permeability |
| Q34972210 | Targeting Neovascularization in Ischemic Retinopathy: Recent Advances |
| Q26852726 | Targeting inflammation in diabetes: Newer therapeutic options |
| Q42920003 | The Optic UK Lecture: bench-to-bedside adventures of a diabetes researcher: results past, results present |
| Q48308877 | The Role of Microglia in Diabetic Retinopathy: Inflammation, Microvasculature Defects and Neurodegeneration. |
| Q28353997 | The absence of diabetic retinopathy in patients with retinitis pigmentosa: implications for pathophysiology and possible treatment |
| Q30845192 | The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy |
| Q37098747 | The immunopharmacologic potential of Semaxanib and new generation directed therapeutic drugs: Receptor tyrosine kinase regulation with anti-tumorigenensis/angiogenesis properties |
| Q37811628 | The paradox of the neutrophil's role in tissue injury |
| Q38242801 | The role of inflammation in the pathogenesis of macular edema secondary to retinal vascular diseases. |
| Q34292435 | The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society |
| Q43051921 | The role of vascular endothelial growth factor in the progression of diabetic vascular complications |
| Q73406082 | The role of vitrectomy in the treatment of diabetic macular edema |
| Q64998563 | Therapeutic Effects of a Novel Phenylphthalimide Analog for Corneal Neovascularization and Retinal Vascular Leakage. |
| Q39214578 | Therapeutic targets of renin-angiotensin system in ocular disorders |
| Q46470767 | Tranilast ameliorates impaired hepatic functions in Schistosoma mansoni-infected mice |
| Q35028866 | Tranilast inhibits protein kinase C-dependent signalling pathway linked to angiogenic activities and gene expression of retinal microcapillary endothelial cells |
| Q83996781 | Transcriptional regulation of aquaporin-3 in human retinal pigment epithelial cells |
| Q35563022 | Treatment of central retinal vein occlusion with triamcinolone acetonide: an optical coherence tomography study. |
| Q36867626 | Using the past to inform the future: anti-VEGF therapy as a road map to develop novel therapies for diabetic retinopathy |
| Q36537262 | Vascular complications of diabetes: mechanisms of injury and protective factors |
| Q35810089 | Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). |
| Q28360225 | Vascular endothelial growth factor and the in vivo increase in plasma extravasation in the hamster cheek pouch |
| Q38572150 | Vasoinhibins prevent retinal vasopermeability associated with diabetic retinopathy in rats via protein phosphatase 2A-dependent eNOS inactivation |
| Q33542927 | Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction |
| Q36049918 | Zingiber officinale attenuates retinal microvascular changes in diabetic rats via anti-inflammatory and antiangiogenic mechanisms |
| Q83957028 | [Early antiexudative response--OCT monitoring after intravitreal bevacizumab injection] |
Search more.